Curlew Bio Joins MTM's Brisbane Pod
Molecule to Medicine announces Curlew Bio as the second venture in its Brisbane Pod, with Uniquest Expansion Fund backing, to develop immunological therapies for inflammatory disease.
Company
Berkeley
Every investor coverage indicates participated in a round Melio Bio raised.
Companies Melio Bio acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Melio Bio. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Molecule to Medicine announces Curlew Bio as the second venture in its Brisbane Pod, with Uniquest Expansion Fund backing, to develop immunological therapies for inflammatory disease.
Weekly agrifoodtech funding roundup covering raises by Nourish Ingredients, AlgiKnit, Allergy Amulet, Bluu Biosciences, Deep Branch, VFC, Waycool, Deliciou and MeliBio, plus Hanegal's acquisition of ready-meal maker Fairdig.